MBLI provides reagents for quantifying PCSK9, which is secretory protein binding to receptor of low-density lipoprotein (LDL) to increase blood levels of LDL cholesterol through suppressing the uptake of LDL cholesterol to liver cells.
MBLI provides reagents for quantifying PCSK9, which is secretory protein binding to receptor of low-density lipoprotein (LDL) to increase blood levels of LDL cholesterol through suppressing the uptake of LDL cholesterol to liver cells.